Post on 03-Oct-2020
Presented by Joan Loken,
President Rocky Mountain Chapter
1
All stock references are meant to be used for educational purposes.
No recommendation for purchase or sale is intended or implied.
Please perform your own due diligence
2
Myriad Genetics, Inc., is engaged in the
discovery and commercialization of
transformative tests which ◦ assess a person's risk of developing disease, ◦
◦ guide treatment decisions and
◦ assess risk of disease progression and
recurrence.
4
Sector: Healthcare
Industry: Diagnostic & Research Services
HQ: Salt Lake City, UT
Sales: 550 Million (low end mid-sized)
Fiscal Year: ends June 30th
GROWTH: Organic with Partnerships and one major acquisition
5
CEO: Dr. Peter Meldrum
EMPLOYEES: 1169
incl. 45 PHD’s & 390 Sales
DEBT: None
Insider Ownership: 6.3%
Repurchased
24% of Shares Outstanding
6
7
8
9
10
11
12
13
14
Own or have license to 193 issued patents in US & foreign countries
Own or have license to 24 patents related to BRAC Analysis testing
Are party to multiple license agreements with rights to use certain technologies for ◦ Research, development of testing processes
◦ Commercialization of molecular diagnostic tests & diagnostic services
15
In 2011 acquired Rules Based Medicine (RBM)
Acquisition expanded test pipeline into new
diseases
Myriad RBM has strategic collaborations with 20
major pharmaceutical & biotechnology companies
Provide biomarker discovery & companion
diagnostic services
16
17
18
Provides companion diagnostic services to:
Pharmaceutical
Biotechnology industries
Medical research institutions
Can benefit from research performed by other organizations to acquire new product testing opportunities
19
20
21
22
23
May not be able to continue to license these
technologies on reasonable terms
Competition is intense in existing and potential
markets
Many potential competitors have greater financial,
technical & marketing resources
Existing molecular tests could be made obsolete
by less expensive or more effective test methods
in the future
24
Changes in healthcare policy
Foreign governments may
impose reimbursement standards
Unable to protect proprietary
technology
25
Defendant in lawsuit brought by Association for
Molecular Pathology on May 12, 2009
After bouncing around in the courts for four years,
now headed to the Supreme Court
U.S. Supreme Court hearing on April 15,
Decision by June 30, 2013
The lawsuit has affected the price of
Myriad stock
26
Link to NPR script of Supreme Court hearing and Justice’s comments http://www.npr.org/blogs/health/2013/04/15/177035299/supreme-court-asks-can-human-genes-be-patented
Wide coverage, read news articles at your
favorite site
Supreme Court Decision By June 30, 2013
27
28
29
30